Phase II and phase III studies showed no difference in terms of efficacy and baseline testosterone levels in men receiving GnRH antagonists for 1 year compared to men receiving various GnRH agonists for their PCa.13 This evidence concerns the gene GNRH1 and posterior cortical atrophy.